The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

Embracing industrial symbiosis goes beyond ethical responsibility; it’s a chance for companies to lower costs, reduce ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Contract manufacturing revenues in the pharmaceutical finished dose sector witnessed a significant slowdown over the past ...

The biggest threat for European pharmaceutical groups currently comes from the United States. President-elect Donald Trump ...

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...

Shares of weight-loss drugmakers like Novo Nordisk and Eli Lilly surged after President Biden proposed expanding anti-obesity drug coverage under state health plans. The move could reduce ...

On October 22, Novo Nordisk (Novo) nominated semaglutide products, which include its popular drugs marketed as Ozempic for type 2 diabetes and ...